Is the efficacy of the pediatric-like protocols for ALL superior to the protocols for adult ALL?
Moderator: R. Foà
Yes: J.P. Marie
No: J.M. Ribera
Should the induction for Ph+ ALL be based on TKI alone or TKI plus chemotherapy?
Moderator: J.P. Marie
TKI Alone: R. Foà
TKI plus chemotherapy: O. Ottmann
Session 7
MULTIPLE MYELOMA (MM)
Multiple Myeloma in patients <70 years: Cure vs. disease control.
Moderator: N. Kröger
Cure: J.F. San-Miguel
Control: M. Boccadoro
Should therapy for newly diagnosed MM be risk adapted?
Moderator: M. Boccadoro
Yes: B. Barlogie
No:E. Terpos
Saturday, September 4, 2010
Hall A
Hall B
08:30-10:00
Session 8
STEMCELL TRANSPLANTATION (SCT) I The role of Allogeneic SCT (AlloSCT) in Hematological Malignancies
How should we treat a 60 year old patient with Myelodysplastic syndrome?
Moderator: M. Martelli
AlloSCT: N. Kröger
Conventional Therapy: U. Platzbecker
Should all adult ALL patients have a stem cell transplantation in first remission or only high risk patients?
Moderator: W. Arcese
All: A. Goldstone
Only high risk: D. Hoelzer
Session 12
COAGULATION
Are there indications for thrombophylaxis in cancer patients during and after chemotherapy?
Moderator: M.M . Samama
Yes: A. Falanga
No: A. Kakkar
Is there still a role for splenectomy in ITP?
Moderator: A. Falanga
Yes: B. Godeau No: J. Bussel
10:30-12:30
Session 9
STEM CELL TRANSPLANTATION (SCT) II
Alternative Donor and Reduced Intensity Conditioning (RIC) AlloSCT
Should CBT, Haploidentical transplant or MUD transplant be considered upfront if no sibling donor is available?
Moderator: A. Rambaldi
CBT: W. Arcese
Haplo: M. Martelli
MUD: A. Bacigalupo
Should we use AlloSCT in Acute Myeloid Leukemia RIC or Myeloablative preparative protocols?
Moderator: A. Bacigalupo
RIC: A. Nagler
Myeloablative: A. Rambaldi
Session 13
CHRONIC MYELOID LEUKEMIA (CML) I
Is mutation analysis of BCR ABL of any value in clinical management of CML patients?
Moderator:J. Goldman
Yes: A. Hochhaus No: D. Marin
Should first line imatinib treatment be optimized by combination with IFN or by higher imatinib dose? Moderator: A. Hochhaus Combination with IFN: F. Guilhot Higher initial imatinib dose: R. Hehlmann
On the road to cure CML, does it matter to hit different pathways?
Do hypomethylating agents improve survival in patients with high risk myelodysplastic syndromes?
Moderator: G. Leone
Yes: V. Santini
No: M. Cazzola
Is there a rationale for iron chelation therapy in MDS?
Moderator: E. Rachmilewitz
Yes: N. Gattermann
No:A. Tefferi
Session 14
CHRONIC MYELOID LEUKEMIA (CML) II
Will second generation TKIs substitute imatinib as first line treatment of CML?
Moderator: R. Hehlmann
Yes: M. Baccarani No:H. Kantarjian
Can we eventually stop TKI in all CML patients?
Moderator:M. Baccarani
Yes: F. Mahon
No: J. Goldman
16:30-18:00
Session 11
HODGKIN AND NON-HODGKIN LYMPHOMA
Has PET/CT an established role in the management of HD and NHLs?
Moderator: M. Björkholm
Yes: M. Hutchings
No: U. Vitolo
Does molecular outcome prediction in DLBCL add clinical value?
Moderator: M. Björkholm
Yes: C. Gisselbrecht
No: M. Pfreundschuh
Session 15 16:30-18:30
HEMOGLOBINOPATHIES & PNH
Pros and cons of gene therapy in beta-thalassemia
Moderator: L. Luzzatto
Lecture: S. Rivella
The controversies in the use of chelating drugs for the treatment of iron overload affect the morbidity and mortality of thalassaemia and other transfused patients worldwide Moderator: E. Rachmilewitz Lecture: G. Kontoghiorghes
How far one should go with iron chelation in thalassemia? Is iron deficiency indicated?
Moderator: E. Rachmilewitz
Yes: V. Berdoukas No: M.D. Cappellini
Do the benefits of complement blockade extend to all patients with PNH clone?
Moderator: M.D. Cappellini
Yes: A.M. Risitano
No:L. Luzzatto
Sunday, September 5, 2010
Hall A
Hall B
08:30-10:00
Session 16
MYELO PROLIFERATIVE NEOPLAMS (MPNs)
Are JAK2 positive PV, ET and IM different diseases?
Moderator: A. Tefferi
Yes: W. Vainchenker No: A.M. Vannucchi
Do JAK2 inhibitors represent a major advance in the treatment of myeloproliferative neoplasms?
Moderator: W. Vainchenker
Yes: A. Tefferi
No: T. Barbui
Session 17
INFECTIONS
Is there a role for empirical or pre-emptive antifungal treatment in patients with hematological malignancies?
Moderator: F. Menichetti
Yes: B. de Pauw No: A. Prentice
Is monitoring of azole concentrations of clinical value in pts with hematological malignancies?
Moderator: B. de Pauw
Yes: F. Menichetti No: P. Donnelly
10:30-12:30
Session 18 PLENARY SESSION 18
Is there a role of biologic prognostic markers in the treatment of CLL?
Moderator: E. Rachmilewitz
For: R. Foà
Against: K. Rai
Are there sufficient indications for switching to new anticoagulant agents?
Moderator: G. Saglio
For: M.M . Samama
Against: A. Falanga
Which is the best chemotherapy regimen in Hodgkin Lymphoma?
Moderator: D. Straus
ABVD: A. Levis
BEACOPP: V. Diehl
Is chemotherapy alone sufficient for the treatment of Hodgkin Lymphoma?
WebStudio.co.il